Sutro Biopharma Inc. (STRO) names Hans-Peter Gerber as Chief Scientific Officer Sep 19, 2023 08:03AM
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer Sep 19, 2023 08:00AM
Sutro Biopharma to Participate in Upcoming Investor Conferences Aug 30, 2023 08:00AM
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones Aug 10, 2023 04:30PM
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration Jun 26, 2023 08:00AM
View Older Stories

Jun 3, 2023 04:00PM Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal S
May 31, 2023 08:00AM Sutro Biopharma to Participate in the Jefferies Healthcare Conference
May 15, 2023 08:00AM Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
May 8, 2023 08:00AM Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
Apr 27, 2023 04:30PM Sutro Biopharma Inc. (STRO) Announces Departure of President of Research & Chief Scientific Officer
Apr 27, 2023 04:30PM Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
Apr 18, 2023 01:30PM Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
Mar 30, 2023 04:30PM Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Mar 17, 2023 04:01PM Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2023 08:00AM Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
Feb 28, 2023 08:01AM Sutro Biopharma (STRO) Appoints Anne Borgman as Chief Medical Officer
Feb 28, 2023 08:00AM Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer  
Feb 17, 2023 04:01PM Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2023 04:05PM Sutro Biopharma (STRO) Reports Updates from STRO-002 Phase 1 Trial
Jan 9, 2023 04:05PM Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Jan 4, 2023 08:00AM Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 21, 2022 08:00AM Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
Dec 20, 2022 04:05PM Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Dec 10, 2022 10:30AM Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
Nov 23, 2022 07:00AM Sutro Biopharma to Participate in Upcoming Investor Conferences
Nov 8, 2022 04:30PM Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Nov 3, 2022 09:00AM Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Nov 2, 2022 07:00AM Sutro Biopharma to Participate in Upcoming Investor Conferences
Oct 24, 2022 07:01AM Sutro Biopharma Inc. (STRO) Announces Chief Medical Officer Departure
Oct 24, 2022 07:00AM Sutro Biopharma Announces Departure of Chief Medical Officer
Sep 1, 2022 07:00AM Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
Aug 19, 2022 04:01PM Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2022 04:30PM Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
Aug 3, 2022 07:00AM Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
Jul 26, 2022 04:04PM Sutro Biopharma Inc. (STRO) Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Jul 26, 2022 04:01PM Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Jul 12, 2022 07:00AM Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
Jun 28, 2022 05:45AM Sutro Biopharma (STRO) and Astellas Enter Global Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Jun 27, 2022 07:31PM Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Jun 27, 2022 07:30PM Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Jun 3, 2022 04:01PM Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2022 07:00AM Sutro Biopharma to Participate in Upcoming Investor Conferences
May 9, 2022 04:30PM Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
Apr 29, 2022 05:00PM Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 8, 2022 01:00PM Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
Apr 5, 2022 07:00AM Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 30, 2022 04:05PM Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC
Mar 3, 2022 07:00AM Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
Feb 28, 2022 04:35PM Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
Jan 6, 2022 07:00AM Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Jan 5, 2022 04:32PM Sutro Biopharma Inc. (STRO) Reports Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
Jan 5, 2022 04:30PM Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
Dec 27, 2021 07:02AM Sutro Biopharma Inc. (STRO) and Tasly Biopharmaceuticals Announce Exclusive License Agreement for STRO-002 in Greater China
Dec 27, 2021 07:00AM Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
Dec 27, 2021 07:00AM Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
View Older Stories